Search results
Juvenile dermatomyositis (JDM) is a rare disease within the group of paediatric rheumatic diseases (PRDs) and can lead to significant morbidity. Evidence-based guidelines are sparse and management is mostly based on physicians' experience. Consequently, treatment regimens differ throughout Europe.
16 sty 2023 · Review the medical treatment of juvenile dermatomyositis. Outline the importance of enhancing care coordination among the interprofessional team to ensure proper evaluation and management of juvenile dermatomyositis.
Juvenile dermatomyositis (JDM) is a rare but complex and potentially life-threatening autoimmune disease of childhood, primarily affecting proximal muscles and skin. Although the cause of JDM remains unknown it is clear that genetic and environmental influences play a role in the aetiology.
The initial guidelines for the treatment of moderately severe JDM were followed by specific clinical treatment plans for JDM beyond the first 2 months , a protocol for the treatment of skin-predominant disease as well as guidelines for the treatment of JDM with a persistent rash .
3 maj 2020 · Juvenile idiopathic inflammatory myopathy is an umbrella entity comprising juvenile dermatomyositis (JDM), juvenile polymyositis (JPM), immune-mediated necrotizing myopathy (IMNM), inclusion body myositis (IBM), and connective tissue disease-associated myositis, which develops before the age of 18 .
What is the treatment for juvenile dermatomyositis? The aim of treatment in juvenile dermatomyositis is to control disease activity and induce remission, prevent long term organ damage and deformity, and improve function and quality of life.
Learn about juvenile dermatomyositis (JDM), an inflammatory disease that affects children's skin and muscles. Find out how to diagnose, treat and prevent JDM with medication, physical therapy and lifestyle changes.
